Department of Cardiology, Heart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the Universities of Kiel and Hamburg, Bad Segeberg, Germany.
Catheter Cardiovasc Interv. 2013 Feb;81(2):285-91. doi: 10.1002/ccd.24367. Epub 2012 May 2.
To assess long-term outcome after rotational atherectomy (RA) is followed by drug-eluting stent (DES) implantation in complex calcified coronary lesions.
RA can favorably modify heavily calcified coronary lesions, but long-term outcome is poor when it is used as a stand-alone therapy or combined with bare-metal stents. DES have reduced rates of restenosis in a wide range of patient and lesion subsets, but little information is available on long-term clinical outcome when RA is followed by DES implantation (Rota-DES) in complex calcified lesions.
Two hundred and five patients with de novo complex calcified coronary lesions treated with Rota-DES were analyzed. Mean age was 69.7 ± 9.3 years, 63 patients (31%) had diabetes mellitus and 21 patients (10%) had chronic renal failure. Total stent length/patient was 32 mm. The majority of patients were treated with paclitaxel-eluting stents (64%) or sirolimus-eluting stents (30%). Angiographic success rate was 98%. The incidence of in-hospital major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), and target vessel revascularization (TVR), was 4.4%. Long-term follow-up was available for 188 patients (92%). At a median follow-up period of 15 months (range, 1-84), the cumulative incidence of MACE (Kaplan-Meier estimate) was 17.7%. Death occurred in 4.4%, MI in 3.4%, TVR in 9.9%, and target lesion revascularization (TLR) in 6.8%. One definite (0.5%) and one probable (0.5%) stent thrombosis were observed. In a multivariate analysis, low ejection fraction (<40%) was the only independent predictor of MACE, and both age and diabetes were independent predictors of TLR.
This study represents the largest European data set of patients treated with RA in the DES era. RA followed by DES implantation in calcified coronary lesions appears to be feasible and effective, with a high rate of procedural success and low incidence of TLR and MACE at long term considering this complex patient and lesion subset.
评估旋磨术(RA)后药物洗脱支架(DES)植入治疗复杂钙化冠状动脉病变的长期结果。
RA 可以很好地改善重度钙化的冠状动脉病变,但作为单独的治疗方法或与裸金属支架联合使用时,其长期结果不佳。DES 在广泛的患者和病变亚组中降低了再狭窄率,但关于 RA 后行 DES 植入(Rota-DES)治疗复杂钙化病变的长期临床结果的信息很少。
分析了 205 例接受 Rota-DES 治疗的新发复杂钙化冠状动脉病变患者。平均年龄为 69.7 ± 9.3 岁,63 例(31%)患有糖尿病,21 例(10%)患有慢性肾衰竭。每位患者的总支架长度为 32mm。大多数患者接受紫杉醇洗脱支架(64%)或西罗莫司洗脱支架(30%)治疗。血管造影成功率为 98%。住院期间主要不良心脏事件(MACE)的发生率定义为死亡、心肌梗死(MI)和靶血管血运重建(TVR)为 4.4%。188 例患者(92%)可获得长期随访。在中位数为 15 个月(范围 1-84 个月)的随访期间,MACE(Kaplan-Meier 估计)的累积发生率为 17.7%。死亡 4.4%,MI 3.4%,TVR 9.9%,TLR 6.8%。观察到 1 例确定(0.5%)和 1 例可能(0.5%)支架血栓形成。多变量分析显示,射血分数低(<40%)是 MACE 的唯一独立预测因素,年龄和糖尿病是 TLR 的独立预测因素。
本研究代表了 DES 时代接受 RA 治疗的最大的欧洲患者数据集。RA 后行 DES 植入治疗钙化冠状动脉病变似乎是可行且有效的,考虑到这一复杂的患者和病变亚组,其具有很高的手术成功率和较低的 TLR 和 MACE 发生率。